Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

1. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

2. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism

Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism Evidence-based Synthesis Program Department of Veterans Affairs Health Services Research & Development Service April 2012 Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism Prepared for: Department of Veterans Affairs Veterans Health Administration (...) . Warfarin and Newer Oral Anticoagulants: Long-term Prevention and Treatment of Arterial and VTE Evidence-based Synthesis Program PREFACE Quality Enhancement Research Initiative’s (QUERI’s) Evidence-based Synthesis Program (ESP) was established to provide timely and accurate syntheses of targeted healthcare topics of particular importance to Veterans Affairs (V A) managers and policymakers, as they work to improve the health and healthcare of Veterans. The ESP disseminates these reports throughout V

2012 Veterans Affairs Evidence-based Synthesis Program Reports

3. Oral anticoagulation with warfarin - 4th edition

Oral anticoagulation with warfarin - 4th edition Guidelines on oral anticoagulation with warfarin – fourth edition - Keeling - 2011 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. guideline Free Access Guidelines on oral anticoagulation with warfarin – fourth edition (...) of this article with your friends and colleagues. Copy URL Share a link ). The guidance is updated with reference to relevant publications since 2005. Publications known to the writing group were supplemented with additional papers identified by searching PubMed for publications in the last 5 years using the key word warfarin and limits clinical trial, randomized control trial, meta‐analysis, humans, core clinical journals, and English language. The writing group produced the draft guideline, which

2011 British Committee for Standards in Haematology

4. ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation

ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: M JIN, REVISED BY: L KOSAR – UPDATED DECEMBER 2012 – WWW.RXFILES.CA Page 1 of 4 ROCKET-AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation 1 Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in AF BOTTOM LINE In atrial fibrillation (AF) patients with an ? risk of stroke (mean CHADS (...) 2 score 3.5), rivaroxaban 20mg po daily: ? Was non-inferior (i.e. no worse than) to warfarin for ? stroke or systemic embolism ? Had less hemorrhagic strokes, systemic embolism & bleeding (critical, fatal & intracranial) versus warfarin ? Had more drops in hemoglobin =20 g/L, tranfusions, gastrointestinal bleeding, epistaxis & hematuria versus warfarin ? At time of publication, rivaroxaban for AF is approximately $100/month; 15mg, 20mg tablets. ? A Fib, ? Warfarin + monitoring ~$35/month

2012 RxFiles

5. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure. Full Text available with Trip Pro

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure. Heart failure (HF) is a common co-morbidity in non-valvular atrial fibrillation (NVAF) patients and a potent risk factor for stroke, bleeding, and a decreased time-in-therapeutic range with warfarin. We assessed the real-world effectiveness and safety of rivaroxaban and warfarin in NVAF patients with co-morbid HF.Using US Truven MarketScan Commercial and Medicare (...) supplemental database claims data from 11/2011 to 12/2016, we identified oral anticoagulant (OAC)-naïve NVAF patients with HF (International Classification of Diseases, 10th Revision codes of I50 or I09.81) and ≥12 months of insurance coverage prior to the qualifying OAC dispensing. Rivaroxaban users (20 or 15 mg once daily) were 1:1 propensity score matched to warfarin users, with residual absolute standardized differences <0.1 being achieved for all covariates after matching. Patients were followed up

2019 ESC heart failure

6. Warfarin Therapy Management

). • Coumadin, www.coumadin.com, for patient information. • HealthLink BC, www.healthlinkbc.ca, for more information on warfarin and vitamin K. ? Appendices • Appendix A: Important Interactions with Warfarin ? Associated Documents The following documents accompany this guideline: • BCGuidelines.ca – Warfarin Therapy – Management During Invasive Procedures and Surgery • BCGuidelines.ca – Stroke and Transient Ischemic Attack – Acute and Long-Term Management • BCGuidelines.ca – Atrial Fibrillation – Diagnosis (...) Warfarin Therapy Management Guidelines & Protocols Advisory Committee Warfarin Therapy Management Effective Date: April 1, 2015 Scope This guideline provides recommendations for the long-term management of warfarin therapy in patients aged =19 years in the primary care setting. The guideline describes: 1) warfarin initiation, 2) international normalized ratio (INR) monitoring with optimal ranges, and 3) warfarin dosage adjustment. This guideline assumes the physician has reviewed

2015 Clinical Practice Guidelines and Protocols in British Columbia

7. Do you have any records of interactions between warfarin and Bachs rescue remedy?

Do you have any records of interactions between warfarin and Bachs rescue remedy? Do you have any records of interactions between warfarin and Bachs rescue remedy? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches (...) types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Do you have any records of interactions between warfarin and Bachs rescue remedy? We have been unable to locate any information stating that there is an interaction between Bachs Rescue Remedy and warfarin. However, please

2008 TRIP Answers

8. The efficacy and safety of new oral anticoagulants versus warfarin in patients with atrial fibrillation: a update meta-analysis of randomised trials

The efficacy and safety of new oral anticoagulants versus warfarin in patients with atrial fibrillation: a update meta-analysis of randomised trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

9. Atrial fibrillation: apixaban (Eliquis) as an alternative to warfarin (Coumadin and other brands) in some situations

Atrial fibrillation: apixaban (Eliquis) as an alternative to warfarin (Coumadin and other brands) in some situations Prescrire IN ENGLISH - Spotlight ''Atrial fibrillation: apixaban (Eliquis°) as an alternative to warfarin (Coumadin° and other brands) in some situations'', 1 June 2019 {1} {1} {1} | | > > > Atrial fibrillation: apixaban (Eliquis°) as an alternative to warfarin (Coumadin° and other brands) in some situations Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most (...) recent :  |   |   |   |   |   |   |   |   |  Spotlight Atrial fibrillation: apixaban (Eliquis°) as an alternative to warfarin (Coumadin° and other brands) in some situations When atrial fibrillation warrants the use of an anticoagulant, the anti-vitamin K warfarin (Coumadin° and other brands) is still the best long-term evaluated oral anticoagulant. The anti-Xa apixaban (Eliquis°) is an alternative in some situations. In patients

2019 Prescrire

10. ARISTOTLE: Apixaban vs Warfarin in patients with Atrial Fibrillation

ARISTOTLE: Apixaban vs Warfarin in patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: M JIN, REVISED BY: L KOSAR – UPDATED NOV 2012 – WWW.RXFILES.CA Page 1 of 3 ARISTOTLE: Apixaban vs Warfarin in patients with Atrial Fibrillation 1 Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation BOTTOM LINE In atrial fibrillation (AF) patients with an ? risk of stroke (mean CHADS 2 score 2.1): • Apixaban 5mg po BID was superior to warfarin (...) for ? stroke or systemic embolism (NNT=167/1.8 years) • Apixaban, compared to warfarin, had: - ? stroke (NNT=175/1.8yr), hemorrhagic stroke (NNT=238/1.8yr) & mortality (NNT=132/1.8yr) - ? bleeding major (NNT=67/1.8yr), intracranial (NNT=128/1.8yr), other & any bleeding & ? discontinuation rates (NNT=45/1.8yr) • Net clinical benefit stroke, systemic embolism, major bleeding or death from any cause favours apixaban over warfarin (NNT=56/1.8 years) • At time of publication, apixaban is not approved by Health

2012 RxFiles

11. Warfarin: Management of Out-of-Range INRs

Warfarin: Management of Out-of-Range INRs © 2015 Thrombosis Canada Page 1 of 6 WARFARIN: MANAGEMENT OF OUT-OF-RANGE INRS OBJECTIVE: To provide practical strategies supported by the best available evidence for managing out-of- range international normalized ratios (INRs) for patients on long-term warfarin therapy. BACKGROUND: ? Warfarin can be challenging to manage due to its narrow therapeutic range, variable dose- response among different patients and common interactions with drugs, diet (...) and other factors. ? In patients who are taking warfarin, thromboembolic events and bleeding are strongly related to the time in therapeutic range (TTR). This is the proportion of treatment time that the INR is within the target therapeutic range (typically 2.0 to 3.0). ? Clinicians may underdose warfarin due to a perceived greater risk of harm from bleeding associated with supratherapeutic INR values. However, subtherapeutic anticoagulation has been shown to increase the frequency and severity

2015 Thrombosis Interest Group of Canada

12. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Full Text available with Trip Pro

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Harrington AR, Armstrong EP, Nolan PE, Malone DC Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of new oral anticoagulants, for stroke prevention, in patients with nonvalvular atrial fibrillation, compared with warfarin. The authors concluded that the anticoagulants were more cost-effective than warfarin, and apixaban was preferred. The study

2013 NHS Economic Evaluation Database.

13. Warfarin vs New Oral Anticoagulants (NOACs) in Non-valvular AFib

Warfarin vs New Oral Anticoagulants (NOACs) in Non-valvular AFib Anticoagulation in Non-valvular 26 AFib www.RxFiles.ca COUMADIN PRADAXA XARELTO ELIQUIS LIXIANA SAVAYSA USA Warfarin Dabigatran 150mg Rivaroxaban Apixaban Edoxaban Stroke/Embolism ? 1 ??? 2 ?? 3 ??? 4 ??? 5 ICH X ? 6 ? 7 ? 8 ? 9 Major GI Bleed ? X 10 X 11 ? 12 X 13 Major Bleed ? ? 14 ? 15 ?? 16 ?? 17 Manage Bleed ? 14 ? 18 X? X? X? MI ? X? 19 -? -? -? DC Rate / Dyspepsia - X 20 /?GI - ? - Low renal fx (CrCl) ?? 21 CI 70%. 1 (...) ) Stroke/Embolism: absolute differences minimal when INR control with warfarin reasonable (TTR=>65%). 2) Stroke/Embolism: Dabi 150mg BID vs Warf; NNT=88/~2yr; ITT (no difference with 110mg BID dose, but less bleeding); open label RCT. (Study pop: renal fx 30+, adherence likely better than normal conditions, etc.) 3) Stroke/Embolism: Riva 20mg daily vs Warf; non-inferiority trial design (ITT analysis favoured Riva but did not achieve superiority); double-blind RCT. (Study pop: limitations similar to RE

2013 RxFiles

14. RE?LY: Dabigatran versus Warfarin in Patients with Atrial Fibrillation

RE?LY: Dabigatran versus Warfarin in Patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: Z.DUMONT, D.BUNKA. REVISED BY L.KOSAR – UPDATED AUG 2013 – WWW.RXFILES.CA Page 1 of 5 RE-LY: Dabigatran versus Warfarin in Patients with Atrial Fibrillation 1 Randomized Evaluation of Long-term anticoagulation therapY in patients with atrial fibrillation & who were at increased risk of stroke BOTTOM LINE In RE-LY, patients with atrial fibrillation (AF) (mean CHADS 2 score 2.1 (...) ): ? Dabigatran both doses had less hemorrhagic strokes & intracranial bleeds. ? Dabigatran 150mg po bid had: - less stroke/systemic embolism 1 ? endpoint, but more gastrointestinal (GI) bleeds compared to warfarin & dabigatran 110mg po bid - a better net clinical benefit compared to warfarin - more major bleeding than dabigatran 110mg po bid but similar to warfarin ? Dabigatran 110mg po bid was similar to warfarin for stroke & systemic embolism, but had less major bleeding than warfarin. - consider

2013 RxFiles

15. Warfarin for thromboembolic prophylaxis in atrial fibrillation: Evidence profile

Warfarin for thromboembolic prophylaxis in atrial fibrillation: Evidence profile

2017 DynaMed Plus

16. Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF. (Abstract)

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF. The management of anticoagulation therapy in patients with atrial fibrillation (AF) and cancer is challenging due to increased thrombotic and bleeding risks. We sought to determine the safety and efficacy of rivaroxaban in patients with AF and a history of cancer.ROCKET AF randomized 14,264 patients with AF to rivaroxaban or warfarin (...) with a median follow-up of 1.9 years. Cox regression models were used to assess the association between cancer history and clinical outcomes, and the relative treatment effect of rivaroxaban versus warfarin in these patients. A total of 640 patients enrolled in ROCKET AF had a history of cancer, with the most common types being prostate (28.6%), colorectal (16.1%), and breast (14.7%) cancer. Patients with a history of cancer were older, more frequently male, more likely to have prior VKA use, and had higher

2018 European heart journal. Quality of care & clinical outcomes Controlled trial quality: predicted high

17. Safety and effectiveness of apixaban compared to warfarin in dialysis patients Full Text available with Trip Pro

Safety and effectiveness of apixaban compared to warfarin in dialysis patients Background: The use of apixaban for stroke prophylaxis or for the treatment of venous thromboembolism in end stage renal disease (ESRD) patients maintained on dialysis is based on one single-dose pharmacokinetic study. There is a deficiency of clinical evidence supporting safety in this population.Objective: The purpose of this study was to determine the safety and efficacy of apixaban compared with warfarin (...) in dialysis patients.Patients/methods: This is a retrospective cohort study conducted at the University of Virginia Medical Center. A total of 124 ESRD patients maintained on dialysis who either received apixaban (n = 74) or warfarin (n = 50) between January 1, 2014 and October 31, 2016 were included in the study. We used multivariable logistic regression to compare the likelihood of patients experiencing a bleeding event based on anticoagulant therapy.Results: The apixaban group experienced fewer overall

2018 Research and Practice in Thrombosis and Haemostasis

18. Direct oral anticoagulants or warfarin for A fib?

Direct oral anticoagulants or warfarin for A fib? Direct oral anticoagulants or warfarin for A fib? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Direct oral anticoagulants or warfarin for A fib? View/ Open Date 2017-08 Format Metadata Abstract A recent study evaluated the effectiveness of 3 direct oral (...) anticoagulants and warfarin in patients with atrial fibrillation. So which agents came out on top? PRACTICE CHANGER: Use direct oral anticoagulants instead of warfarin in patients with atrial fibrillation because they are just as effective at preventing ischemic stroke and systemic emboli as warfarin, and because apixaban and dabigatran have lower bleeding rates. Stength of recommendation: B: Based on a single, prospective, cohort study. URI Part of Citation Journal of Family Practice, 66(8) 2017: 518-520

2018 PURLS

19. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness

Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism (...) : a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies

2014 Health Technology Assessment (HTA) Database.

20. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial Full Text available with Trip Pro

Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial Chronic heart failure remains a major cause of mortality and morbidity. The role of antithrombotic therapy in patients with chronic heart failure has long been debated. The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus (...) rhythm.This prospective, randomized clinical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double-blind treatment with either aspirin (162 mg once daily) or clopidogrel (75 mg once daily) had a 30-month enrollment period and a minimum of 12 months of treatment. We enrolled 1587 men and women >/=18 years of age with symptomatic heart failure for at least 3 months who were in sinus rhythm and had left ventricular ejection fraction of

2009 EvidenceUpdates Controlled trial quality: predicted high